R&D Pipeline

Vaccinepipeline

PPV-06 : Anti-IL-6 immunotherapy


Peptinov’s anti-IL-6 immunotherapy is now its most advanced product and is ready for pre-clinical and clinical development.

PPV-06 test results have demonstrated:

– a protective effect in a mouse systemic sclerosis model (published results),

– induction of neutralizing anti-human IL-6 antibodies after immunizations in rabbits,

– induction of significant levels of anti-human IL-6 antibodies and of a protective effect against the inflammation linked to the Delayed-Type Hypersensitivity response in monkeys using a peptide sequence which is identical in monkey and human IL-6 (Desallais et al., Sci Rep, 2016).

Based on these results, Peptinov believes the first human clinical trials for this immunotherapy can be completed within a 2-year timeframe. Peptinov’s PPV-06 anti-IL-6 immunotherapy is currently being evaluated in regulatory toxicity studies which will be completed in September 2018.

Why IL-6? 

IL-6 is a pro-inflammatory cytokine, whose overproduction has been involved in the pathogenesis of several chronic diseases such as osteoarthritis, rheumatoid arthritis, systemic sclerosis or Horton’s disease.

IL-6 has already been validated as a relevant therapeutic target for the treatment of chronic inflammatory diseases. Several monoclonal antibodies targeting such as Actemra (tocilizumab, anti-IL-6R antibody) or Sylvant (siltuximab, anti-IL-6 antibody) are already approved for the treatment of diseases such as rheumatoid arthritis or Castleman’s disease.

Furthermore, the role of IL-6 in the pathogenesis of osteoarthritis has been established.

PPV-01 : Anti-IL-1b immunotherapy


IL-1b is a pro-inflammatory cytokine whose overproduction has been involved in the pathogenesis of several chronic inflammatory diseases such as rheumatoid arthritis, CAPS syndromes or atopic dermatitis.
Targeting IL-1b has also been validated as a relevant therapeutic strategy, as demonstrated by the development of anakinra or canakinumab.

PPV-01 test results have demonstrated:
– protective effect in a mouse rheumatoid arthritis model,
– induction of neutralizing anti-human IL-1 antibodies after immunizations in rabbits,
– induction of neutralizing anti-human IL-1 antibodies after immunizations in rhesus monkeys.

PPV-03 : Anti-IL-23p19 immunotherapy


IL-23 is a pro-inflammatory cytokine whose overproduction has been involved in the pathogenesis of chronic inflammatory diseases such as psoriasis or Crohn’s disease.

The use of ustekinumab for the treatment of psoriasis has validated IL-23 as a relevant therapeutic target. IL-23 is composed of two sub-units: IL-23p19, which is specific to IL-23, and IL-23p40 which is shared by IL-12. 

PPV-03 test results have demonstrated:
– protective effect in a mouse rheumatoid arthritis model,
– induction of neutralizing anti-human IL-23 antibodies after immunizations in rabbits.

 Grant applications are underway to fund continued development.